Browsing Tag
Q3 2025 results
11 posts
PACS Group (NYSE: PACS) stock soars 149% in five days as restatement clears audit cloud and Q3 earnings beat forecasts
PACS Group stock surges 149 percent in five days after restatement and Q3 earnings beat. Find out what’s driving investor confidence and what to watch next.
Air Industries Group (AIRI) cuts net loss by 89% in Q3: Can EBITDA momentum last?
Air Industries Group reports improved margins and EBITDA in Q3 2025. Read how this aerospace manufacturer is positioning for a stronger year-end.
Why Hilton Food Group plc (LSE: HFG) shares fell 22% after its Q3 update despite stable food volumes
Hilton Food Group plc shares plunged 22% after its Q3 2025 update. Learn what triggered the drop, the future profit outlook, and how investors are reacting.
Smith+Nephew Q3 2025: Can the CATALYSTEM rollout and REGENETEN momentum offset VBP risks?
Smith+Nephew raises 2025 free cash flow guidance to USD 750 million as margin growth accelerates. Find out what’s driving the company’s transformation.
Energy Transfer Q3 2025 results miss expectations despite record NGL and pipeline volumes
Find out how Energy Transfer balanced record volumes and lower profits in Q3 2025—and what it means for midstream investors.
Zotefoams (LSE: ZTF) stock tumbles 15% after Q3 2025 update, despite full-year outlook and Asia expansion push
Zotefoams shares drop 15% after Q3 update despite reaffirming FY25 outlook and Vietnam JV expansion. Read the full story on what drove the selloff.
Aker Solutions raises full-year revenue outlook as Q3 2025 results show strong margin resilience and OneSubsea contribution
Aker Solutions ASA beats expectations in Q3 2025, raises full-year guidance above NOK 60B. Find out what rising margins and JV income mean for investors.
Is Shell plc redefining what an oil major looks like in the 2020s? Why marketing and LNG now drive the cash machine
Shell plc's Q3 2025 results show how Marketing and LNG have become core cash engines. Find out how the company is reshaping the oil-major model for a new era.
Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat
Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets.
ULVR stock: Is Unilever’s Q3 volume-led growth and Ice Cream demerger enough to unlock value?
Unilever PLC’s Q3 2025 earnings show 3.9% sales growth and progress on its Ice Cream demerger. Is this the start of a value unlock? Find out now.